Oncobiologics (NASDAQ:OTLK) Stock Picked Up by Analysts at Piper Sandler

Equities research analysts at Piper Sandler assumed coverage on shares of Oncobiologics (NASDAQ:OTLK – Get Free Report) in a note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating on the stock.

Several other equities research analysts have also issued reports on the company. Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. BTIG Research reissued a “buy” rating and set a $4.00 target price on shares of Oncobiologics in a research report on Friday, August 14th. HC Wainwright increased their price target on Oncobiologics to $1.60 and gave the company a “neutral” rating in a report on Monday, July 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oncobiologics in a report on Tuesday, November 10th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.20.

Get Our Latest Research Report on Oncobiologics

Oncobiologics Trading Down 2.7%

OTLK opened at $0.39 on Thursday. Oncobiologics has a 12 month low of $0.16 and a 12 month high of $2.54. The stock has a 50-day moving average of $0.54 and a 200 day moving average of $0.66.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncobiologics stock. NewEdge Advisors LLC bought a new stake in shares of Oncobiologics, Inc. (NASDAQ:OTLK – Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 16,722 shares of the company’s stock, valued at approximately $27,000. Institutional investors and hedge funds own 11.20% of the company’s stock.

About Oncobiologics

(Get Free Report)

Oncobiologics, Inc. changed its name to Outlook Therapeutics, Inc. in 2018 and trades under the symbol OTLK. The biotechnology company focuses on developing and commercializing treatments for eye diseases. Its lead product, Lytenava (bevacizumab gamma), is an ophthalmic formulation of bevacizumab developed to treat neovascular age-related macular degeneration, also known as wet AMD. The company has pursued regulatory approvals and commercialization of the treatment in the United States and Europe.

Further Reading

Analyst Recommendations for Oncobiologics (NASDAQ:OTLK)

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.